In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.
December II 2025
During a live event, Lori Wirth, MD, discussed preferred treatment for thyroid cancer with and without a RET, NTRK, or ALK fusion.
During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.
During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.
During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.
During a live event, Randy F. Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.
During a live event, Lori Wirth, MD, discussed next steps for treating a patient with progressive, radioactive iodine–refractory differentiated thyroid cancer.
During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when choosing frontline regimens for advanced renal cell carcinoma.
During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of amivantamab/lazertinib in EGFR-mutated lung cancer.